Long-term Results of ChlVPP Chemotherapy for Hodgkin's Disease
Author Information
Author(s): P. Selby, P. Patel, S. Milan, M. Meldrum, J. Mansi, E. Mbidde, M. Brada, T. Perren, G. Forgeson, M. Gore, I. Smith, T. McElwain
Primary Institution: Institute of Cancer Research, Royal Marsden Hospital
Hypothesis
The ChlVPP chemotherapy regimen is effective and less toxic than traditional MOPP chemotherapy for Hodgkin's disease.
Conclusion
ChlVPP chemotherapy shows high complete remission rates and lower toxicity compared to MOPP, making it a preferable treatment option.
Supporting Evidence
- 85% of previously untreated patients entered complete remission.
- 91% of previously irradiated patients entered complete remission.
- 71% of previously untreated patients remain in complete remission at 10 years.
- 68% of previously irradiated patients remain in complete remission at 10 years.
- The 10-year actuarial risk of acute leukaemia was 2.7%.
- ChlVPP is as effective and less toxic than MOPP chemotherapy.
Takeaway
Doctors used a special medicine called ChlVPP to help people with a sickness called Hodgkin's disease, and it worked really well without making them too sick.
Methodology
Patients received ChlVPP chemotherapy and were followed for a median of 92 months to assess remission and survival rates.
Potential Biases
Selection bias may have occurred as patients were chosen based on their response to treatment.
Limitations
The study was conducted at a single center and may not represent broader populations.
Participant Demographics
Patients included 284 adults with advanced Hodgkin's disease, with a median age of 30 years.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website